Product Information
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE is a generic product labeled by Ingenus Pharmaceuticals LLC, priced at $2.3760 per EA under NDC 50742028313. Its NADAC has been published 136 times since Jan 17, 2024.
FDA first approved this application on Jul 3, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE
Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochlorideStrength
140; 125; 125 mg/1; mg/1; mg/1
Manufacturer
Ingenus Pharmaceuticals LLCNDC
50742028313
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA217511FDA Approved
7/3/2023
TE Code
AB
On Market Since
7/4/2023
Pharmacological Classes
Price Statistics
The NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has been published 136 times since Jan 17, 2024, and over the history we have for it it has declined 53.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.3760 per EA |
|---|---|
| All-time high | $5.1282 (Feb 14, 2024) |
| All-time low | $2.3760 (Aug 19, 2026) |
| 52-week high | $4.0294 |
| 52-week low | $2.3760 |
| Median price | $3.6473 |
| Average price | $3.5819 |
| Largest weekly change | -22.6% (Jul 17, 2024) |
| Weeks tracked | 136 |
| Tracking since | Jan 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE, manufactured by Ingenus Pharmaceuticals LLC, is $2.3760 per EA (NDC 50742028313), effective Aug 19, 2026.
How has the price of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has declined 53.7%. It has been tracked across 136 weekly CMS publications since Jan 17, 2024.
What are the highest and lowest recorded NADAC prices for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
Since Jan 17, 2024, the NADAC for BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE has ranged from a low of $2.3760 (Aug 19, 2026) to a high of $5.1282 (Feb 14, 2024), with a median of $3.6473 per EA.
Are there cheaper alternatives to BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE?
BISMUTH-METRONIDAZOLE-TETRACYCLINE 140-125-125 MG CAPSULE (NDC 50742028313) is labeled by Ingenus Pharmaceuticals LLC, and CMS classifies it as a generic product.